The New Treatment Advances Changing The Myelofibrosis Landscape

The treatment of myelofibrosis is changing as researchers find new ways to manage the disease and its symptoms. Recent updates from the ASCO Post highlight several areas of progress. This article covers new tools for monitoring health from home, and the role of artificial intelligence in finding new medicines. 

You will also find data on drug combinations like pelabresib and ruxolitinib, as well as updates on stem cell transplant safety and the potential of CAR T-cell therapy. These updates focus on improving daily health and long-term stability for those with myelofibrosis.

Artificial Intelligence in myelofibrosis 

Researchers are using artificial intelligence (AI) to find better ways to treat myelofibrosis. In a recent study, a deep learning system analyzed 150,000 individual cells to see how diseased cells differ from healthy ones. The AI helped find new molecules that can correct the behavior of diseased cells without stopping the body from making healthy red blood cells. This research is still in early testing, but it may lead to medicines with fewer side effects.

Improving platelet levels after stem cell transplant (SCT)

Recovering from a stem cell transplant is a slow process. This is because new cells need time to begin working in the body. One major challenge is keeping enough platelets in the blood to prevent bleeding. A study recently tested an oral medicine called avatrombopag. This medicine sends signals that encourage the body to produce its own platelets more quickly. The results showed that people taking this medicine reached safe platelet levels faster and needed fewer blood transfusions.

Long-term results from the MANIFEST-2 study

The MANIFEST-2 study recently shared results from a 96-week period. It looked at how the drug pelabresib works when combined with ruxolitinib (a common therapy used in myelofibrosis). The data showed that 91.5% of patients who stayed on the combination therapy maintained a smaller spleen size. In comparison, only 57.5% of those taking ruxolitinib alone maintained a smaller spleen size. Pelabresib appears to work by addressing inflammatory proteins that other treatments might miss. Additionally, the combination helped improve red blood cell function and reduced the need for transfusions over two years.

Managing anemia with elritercept

The RESTORE trial is looking at a medication called elritercept. This is intended to help the body produce healthy blood cells by focusing on a specific protein called activin A. The study found that elritercept, whether used alone or with ruxolitinib, helped improve hemoglobin levels. In the trial, 39% of participants saw a reduction in spleen size, and 73% reported that their symptoms felt better managed. The FDA has given this treatment a Fast-Track designation to speed up its review.

Ruxolitinib use during transplants has shown a remarkable improvement in survival

New research shows that ruxolitinib is an important part of the transplant process. It can be used before, during, and after a stem cell transplant to help improve survival rates. A study of people undergoing transplants showed an 82% survival rate at the two-year mark. The data suggest that starting the medication early and managing the dose carefully helps people stay on the therapy longer and maintain a better quality of life. 

CAR T-cell therapy in myelofibrosis

Researchers are testing CAR T-cell therapy for myelofibrosis, specifically for people with the CALR gene mutation. While CAR-T is used for other blood cancers, myelofibrosis is harder to treat because it is difficult to find a marker that isn't also on healthy cells. Scientists at University College London found that mutated calreticulin is a specific marker they can use. Early results show that modified T-cells can remove cancer cells while leaving healthy stem cells alone. Human trials are the next step for this potential one-time treatment.

Using remote tools to identify infections early

Technology now helps people with blood cancer stay connected to their medical teams without leaving home. Because cancer treatments can lower the immune system, infections are a serious risk that can lead to hospital stays. A recent study found that remote monitoring tools allow patients to report symptoms like a cough or a fever immediately. When doctors see these updates in real-time, they can prescribe medicine quickly. This system has helped decrease emergency room visits and allows people to stay in their own homes while they recover.

More exciting news to come in the following years for myelofibrosis patients 

The landscape for myelofibrosis treatment is shifting toward more durable, combination-based strategies and targeted immunotherapies. 

From the long-term success of the pelabresib and ruxolitinib combination in shrinking spleens and improving survival to the promising anemia management seen with elritercept, patients now have more options to address the underlying biology of their disease.

Furthermore, the refined use of ruxolitinib in the transplant setting and the emerging potential of CAR T-cell therapy for specific mutations suggest that personalized, highly effective care is becoming a reality. As these clinical trials progress, the focus remains on managing symptoms and achieving long-term remission and improving the patients’ quality of life.

Read more news like this and stay tuned for our community events and programs with the HealthTree newsletter. 

SUBSCRIBE TO NEWSLETTER 

Source: 

• Myelofibrosis: Treatment Landscape Is Poised for Change